Search
for
Sort by
Research 391–420 of 1000+
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- JAK inhibitors in dermatology: The promise of a new drug class
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- JAK Inhibitors in the Treatment of Alopecia Areata: Efficacy, Safety, and Long-term Outcomes
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- 570 Targeting JAK/STAT and Wnt/b-catenin pathways and 5a-reductase activity to develop an effective anti-hair loss product
- Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
- TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold
- THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
- The JAK/STAT signaling pathway: from bench to clinic
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- Janus Kinase inhibitors in dermatology: a review
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Biologic Therapies and Small-Molecule Inhibitors for Dissecting Cellulitis of the Scalp: A Systematic Review
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Jak inhibitors in the treatment of alopecia areata - a literature review
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
- Hair growth–promoting effects of Enz_MoriL on human dermal papilla cells through modulation of the Wnt/β-Catenin and JAK-STAT signaling pathways